BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
UBS
AstraZeneca
US Army
Cerilliant
Cipla
Johnson and Johnson
Federal Trade Commission
Healthtrust
Mallinckrodt

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,602,911

« Back to Dashboard

Which drugs does patent 6,602,911 protect, and when does it expire?

Patent 6,602,911 protects SAVELLA and is included in one NDA.

This patent has fourteen patent family members in nine countries.
Summary for Patent: 6,602,911
Title: Methods of treating fibromyalgia
Abstract:The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s): Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:10/028,547
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 6,602,911

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe MANAGEMENT OF FIBROMYALGIA (FM) ➤ Subscribe
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe MANAGEMENT OF FIBROMYALGIA (FM) ➤ Subscribe
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe MANAGEMENT OF FIBROMYALGIA (FM) ➤ Subscribe
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe MANAGEMENT OF FIBROMYALGIA (FM) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,602,911

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,635,675 Method of treating chronic fatigue syndrome ➤ Subscribe
7,915,246 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Subscribe
6,992,110 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Subscribe
7,820,643 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Subscribe
7,888,342 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,602,911

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 552856 ➤ Subscribe
Australia 2003268020 ➤ Subscribe
Canada 2467356 ➤ Subscribe
Canada 2493490 ➤ Subscribe
China 1671368 ➤ Subscribe
European Patent Office 1463528 ➤ Subscribe
European Patent Office 1545489 ➤ Subscribe
European Patent Office 2322225 ➤ Subscribe
Spain 2395462 ➤ Subscribe
Spain 2433080 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Harvard Business School
Daiichi Sankyo
Colorcon
Merck
Chubb
Medtronic
Cipla
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot